CClinicalTrials.gg
CompletedNCT00166673Updated Sep 5, 2016

Pilot Study of the Navigator Continuous Glucose Monitor

A Phase 2/3 interventional study of FreeStyle Navigator Continuous Glucose Monitoring System in Diabetes Mellitus, Insulin-Dependent, sponsored by Jaeb Center for Health Research. Completed at 6 sites in United States. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-09-05.

Sponsored by Jaeb Center for Health Research · Phase 2/3 and Interventional

Phase
Phase 2/3
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
3 Years to 17 Years
Sex
All
01

Study summary

This study is being done to find out how accurate the Navigator continuous glucose monitor is in children. It is also being done to see if use of the Navigator can improve blood sugar control and help prevent low blood sugar events. This study has three basic parts: Use of the Navigator at home for one week without being able to see the blood sugar readings; a Baseline visit or a 24-hour admission to a research unit of the hospital to find out how well the Navigator measures the blood sugar; and then 3 months use of the Navigator at home as an aid to diabetes care.

Read the detailed description

Approximately 60 children will be recruited from five centers in the United States to participate in this study. The information gained from this study will be used to plan a larger study in which half of the patients will use the Navigator and half will not. Children who participate in this study will not be eligible to take part in the larger study.

The Navigator provides a glucose reading every 60 seconds (or 1440 readings a day). Each sensor is designed to provide readings for up to 120 hours. It has alarms for hypoglycemia and hyperglycemia and for projected high and low glucose values. The alarm set points can be adjusted by the user. The Navigator also has a trend arrow indicating the glucose rate of change (>-2 mg/dL/min, -2 to -1 mg/dL/min, -1 to 1 mg/dL/min, 1 to 2 mg/dl/min, and >2 mg/dl/min). Subjects can enter events, such as when they took insulin, ate, or exercised. The sensor requires calibration values to be entered 3 times during the first day of wear at 1-hour, 3-hours, and 24-hours and does not require additional calibration values. The values are entered directly into the Navigator which has a TheraSense Freestyle home glucose meter built into the unit. The Navigator has not yet been approved by the FDA. The Navigator currently under review by the FDA will limit sensor wear to 3 days.

Beginning the Study

When a child enters the study, the following will be done:

  1. Questionnaires will be completed.

    • Parents and children (if at least 9 years old) will be asked to fill out questionnaires on a computer in the clinic. The questions will be about the child's diabetes, how the diabetes is being treated, and how the diabetes affects the parent and child.
    • Children who are using insulin pump therapy and are at least 9 years old and parents will be interviewed about the child's diabetes management habits at home. The interview will be conducted by phone by trained interviewers who are at Nemours Children's Clinic in Jacksonville, Florida, one of the study sites.
  2. Blood will be drawn to measure glycosylated hemoglobin (HbA1c).
  3. Parents and children will be instructed on using the Navigator. The first sensor will be inserted by the parent or child with guidance from the study nurse. During the first week, the parent and child will not be able to see the results from the Navigator.
  4. Children will be asked to do the following before returning for the Baseline Visit or the hospital stay about 1 week later:

    • Check the blood sugar using the Freestyle meter built into the Navigator at least 4 times a day
    • Wear the Navigator sensor everyday and change the sensor at the end of day 5
    • On the day a new sensor is started, do 3 fingerstick blood sugar readings using the built-in Freestyle meter to calibrate the Navigator
    • Enter a meal marker event into the Navigator each time your child has a meal or snack
    • Insert a new sensor 1, 2, 3, or 4 days before your child will stay in the hospital
    • Bring any used sensors, including the packaging and inserting device to the Baseline Visit or hospital stay

Baseline Visit Children who are using Lantus with MDI therapy will return for a Baseline Visit approximately one week (7-12 days) after the enrollment visit.

Hospital Stay Those children who are using insulin pump therapy will return for a hospital stay approximately one week (7-12 days) after the enrollment visit and will use the Navigator for about 24 hours. The last sensor that was placed at home will continue to be worn during the hospital stay. A new sensor will also be placed so that your child has 2 sensors inserted during the hospital stay to see how closely the 2 sensors agree.

A CGMS sensor will be inserted and calibrated one hour later.

A small tube called a catheter will be placed in a vein in the child's arm and will stay in the vein while the child is in the hospital. From this tube, a very small blood sample will be drawn every 30 minutes during the hospital stay. After breakfast, blood samples will be taken about every 10 minutes for about an hour. For children who are at least 7 years old, blood samples will be taken about every 20 minutes during a period of exercise in the afternoon.

Procedures at Home after the Baseline Visit or Hospital Stay

  1. Use the Navigator.

    • The Navigator should be worn all of the time for 3 months.
    • The sensor must be replaced every 5 days.
    • With each sensor wear 4 blood sugar readings must be done using the built-in Freestyle meter to calibrate the Navigator.
    • Enter a meal marker event into the Navigator each time a meal or snack is eaten.
    • Children may be asked to insert a new sensor 5 days before some of the study visits to allow the study personnel to look at the skin after the sensor has been worn for 5 days.
  2. Download the Navigator - Once a week, children will need to download the glucose results from the Navigator, which will then be emailed to the study coordinating center.
  3. Use Algorithms for Diabetes Management Decisions - The study doctor or nurse will give the parents and children instructions (Algorithms) for how to make changes to diabetes management from the results of the Navigator. The instructions will be used by the parents and children to make decisions as they receive the results from the device.
  4. Phone Interviews - After 3 days and 2, 4, 8, and 10 weeks after the children leave the hospital, one of the staff will call to see how they is doing with the Navigator and the instructions for diabetes management decisions. We will ask what the child ate in the last meal before the call. We also will ask if the child has been sick or under any stress. For females who have started menstruating, we will ask about her menstrual cycle.

Study Visits

Children will return to the diabetes clinics for visits 1, 3, 7, and 13 weeks after the hospital stay. At these visits, the following will be done:

  1. Any used sensors, including the packaging and inserting device will be collected.
  2. The skin will be looked at where the Navigator has been worn.
  3. The Navigator and the child's insulin pump will be downloaded and reviewed with the parent and child.
  4. The diabetes management instructions will be reviewed with the parent and child to determine if the instructions have been helpful or if they need to be changed.

At the 3, 7, and 13- week visits, parents and children (if at least 9 years old) will be asked to complete a questionnaire about how much you liked or disliked the instructions that were given for using the results of the Navigator.

At the 7-week visit, the following will also be done in addition to the child's regular clinic visit:

  1. Blood will be drawn to measure the HbA1c.

At the 13-week visit, the following will also be done in addition to the child's regular clinic visit:

  1. Blood will be drawn to measure the HbA1c.
  2. Questionnaires will be completed

    • Parents and children (if at least 9 years old) will be asked to complete the same questionnaires and the phone interview that were done during the first visit.
    • Parents and children will be asked to complete one more questionnaire about how much they like using the Navigator.
  3. If the children are willing to continue using the Navigator, they will be given additional sensors to use as often as they would like and they will return for another regular clinic visit in about 3 months (26-week visit). At that visit, the skin will be looked at where the Navigator was used, the HbA1c will be measured, and the parents and children will be asked to complete the same questionnaires that were completed at the 13-week visit about how much they liked using the Navigator and the instructions that were given for using the results of the Navigator.

Those who decide to continue using the Navigator will be seen again at 26-weeks.

  • At the 26-week visit, subjects will be given the choice to continue in the study until the device is approved by the FDA or until Abbott Diabetes Care can no longer provide supplies for the study. Subjects who agree to continue in the study will sign an addendum to the informed consent.
  • Subjects who continue in the study will return to the clinic every 3 months for a follow-up visit. The same procedures completed during the 26-week visit will be completed at each subsequent visit.
02

Conditions studied

  • Diabetes Mellitus, Insulin-Dependent

Keywords

  • Diabetes Mellitus, Insulin-Dependent
  • Type 1 Diabetes
  • Continuous Glucose Monitoring Devices
  • Electronic Data Collection
03

In context

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's enrollment of 60 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

Jaeb Center for Health Research is the lead sponsor of 126 studies on the registry; 17 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Clinical diagnosis of type 1 diabetes and using daily insulin therapy for at least one year The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not needed.
  • Age 3.0 years to less than 18.0 years
  • Subject has used a downloadable insulin pump or Lantus with MDI of a short-acting insulin (e.g. Humalog or Novolog) for at least 6 months
  • Parent/guardian and subject understand the study protocol and agree to comply with it
  • Subjects >9.0 years old and primary care giver (i.e., parent or guardian) comprehend written English
  • Subject has a home computer with email access
  • For females, subject not intending to become pregnant during the next 3 months
  • No expectation that subject will be moving out of the area of the clinical center during the next 3 months
  • Informed Consent Form signed by the parent/guardian and Child Assent Form signed by the subject

Exclusion criteria

Exclusion Criteria:

  • The presence of a significant medical disorder that in the judgment of the investigator will affect the wearing of the sensors or the completion of any aspect of the protocol.
  • The presence of any of the following diseases:

    • Asthma if treated with systemic or inhaled corticosteroids in the last 6 months
    • Cystic fibrosis
    • Other major illness that in the judgment of the investigator might interfere with the completion of the protocol (Adequately treated thyroid disease and celiac disease do not exclude subjects from enrollment)
  • Inpatient psychiatric treatment in the past 6 months for either the subject or the subject's primary care giver (i.e., parent or guardian).
  • Current use of oral/inhaled glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study.
05

Study design

Phase
Phase 2 / Phase 3
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants

Interventions

  • DeviceFreeStyle Navigator Continuous Glucose Monitoring System
06

What researchers measure

Primary outcomes

  1. Feasibility of using the Navigator sensor on a daily basis (Average number of sensors used per week, Average number of hours of use per sensor, Number of sensors per week that fail to calibrate)

  2. Navigator Accuracy

Secondary outcomes

  1. Psychosocial Questionnaires

  2. Exploratory assessment of impact of Navigator on HbA1c

07

Study locations

6 sites
  • Division of Pediatric Endocrinology and Diabetes, Stanford University
    Stanford, California 94305-5208, United States
  • Barbara Davis Center for Childhood Diabetes, University of Colorado
    Aurora, Colorado 80010, United States
  • Department of Pediatrics, Yale University School of Medicine
    New Haven, Connecticut 06519, United States
  • Nemours Children's Clinic
    Jacksonville, Florida 32207, United States
  • Jaeb Center for Health Research
    Tampa, Florida 33647, United States
  • Department of Pediatrics, University of Iowa Carver College of Medicine
    Iowa City, Iowa 52242, United States
08

References and documents

Publications

  • Buckingham B, Ruedy K, Kollman C, Beck R, Tamborlane W, Mauras N, Weinzimer S, Chase P, Tsalikian E; and the Diabetes Research in Children Network (DirecNet) Study Group. Family Assessment of the Utility of the DirecNet Applied Treatment Algorithm (DATA) for Insulin Adjustments in Real-Time and Retrospective Analyses of Continuous Glucose Monitoring (CGM) Diabetes 2006; 55(Suppl.1): A453
  • Fiallo-Scharer R, Tamborlane W, Buckingham B, Wysocki T, Weinzimer S, Tsalikian E, Beck R, Ruedy K, Kollman C; and the Diabetes Research in Children Network (DirecNet) Study Group. Diabetes Research in Children Network (DirecNet) Pilot Study to Evaluate the FreeStyle Navigator® Continuous Glucose Monitoring System in the Management of T1D in Children. Diabetes 2006; 55(Suppl.1): A452.
  • Wilson DM, Beck RW, Tamborlane WV, Dontchev MJ, Kollman C, Chase P, Fox LA, Ruedy KJ, Tsalikian E, Weinzimer SA; DirecNet Study Group. The accuracy of the FreeStyle Navigator continuous glucose monitoring system in children with type 1 diabetes. Diabetes Care. 2007 Jan;30(1):59-64. doi: 10.2337/dc06-1407. PubMed 17192334 ↗
  • Diabetes Research in Children Network (DirecNet) Study Group. Relative accuracy of the BD Logic and FreeStyle blood glucose meters. Diabetes Technol Ther. 2007 Apr;9(2):165-8. doi: 10.1089/dia.2006.0005. PubMed 17425442 ↗
  • Diabetes Research in Children Network (DirecNet) Study Group; Buckingham B, Beck RW, Tamborlane WV, Xing D, Kollman C, Fiallo-Scharer R, Mauras N, Ruedy KJ, Tansey M, Weinzimer SA, Wysocki T. Continuous glucose monitoring in children with type 1 diabetes. J Pediatr. 2007 Oct;151(4):388-93, 393.e1-2. doi: 10.1016/j.jpeds.2007.03.047. Epub 2007 Aug 24. PubMed 17889075 ↗
  • Messer L, Ruedy K, Coffey J, Englert K, Caswell K, Steffen A; and the Diabetes Research in Children Network (DirecNet) Study Group. Pediatric Educators' Role in Successful Continuous Glucose Monitoring. Diabetes 2007; 56(Suppl.1): A617.
  • Diabetes Research In Children Network (DirecNet) Study Group; Buckingham B, Xing D, Weinzimer S, Fiallo-Scharer R, Kollman C, Mauras N, Tsalikian E, Tamborlane W, Wysocki T, Ruedy K, Beck R. Use of the DirecNet Applied Treatment Algorithm (DATA) for diabetes management with a real-time continuous glucose monitor (the FreeStyle Navigator). Pediatr Diabetes. 2008 Apr;9(2):142-7. doi: 10.1111/j.1399-5448.2007.00301.x. Epub 2008 Jan 24. PubMed 18221427 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 5, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00166673
Lead sponsor
Jaeb Center for Health Research
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Responsible party
Sponsor
First posted
Sep 14, 2005
Start date
Aug 2005
Completion
Aug 2007
Last update
Sep 5, 2016

Study contacts

William V Tamborlane, M.D.
study chair · Yale University
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion